News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rexahn Pharmaceuticals, Inc. (RNN) Receives A Notice Of Allowance From The U.S. Patent And Trademark Office For A Novel Targeted Cancer Drug Delivery Platform



9/3/2014 8:41:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced it has received a notice of allowance from the United States Patent and Trademark Office for a new delivery technology titled, “Polymeric Systems for the Delivery of Anticancer Drugs”. The patent covers CPMA, a new polymer drug delivery platform technology developed by Rexahn.

“We are pleased to further expand our platform of proprietary drug delivery technologies in preclinical development. CPMA complements our nano-polymer-drug delivery platform, nano-polymer-drug conjugate system (NPDCS), which has already shown promising results in preclinical studies,” stated Rexahn’s CEO, Peter D. Suzdak, Ph.D. “Our drug delivery platforms address a well-recognized need in cancer treatment for drugs that selectively target and kill cancer cells, while leaving healthy cells unharmed. Although numerous widely used FDA-approved anti-cancer drugs offer benefits to patients, in most cases, the efficacy of these drugs can be significantly improved, and their toxic side-effects minimized, if they can be combined with a targeted drug delivery technology to bring the drug directly into cancer cells.”

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES